Meeting
2011 ASCO Annual Meeting
A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
Authors
A. R. Townsend
The Queen Elizabeth Hospital, Adelaide, Australia
A. R. Townsend , L. Pirc , J. Hardingham , C. S. Karapetis , N. C. Tebbutt , N. Singhal , T. J. Price
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01139138
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS162)
Abstract #
TPS162
Poster Bd #
43H
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
![PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. .](https://d201v5jt9ylckg.cloudfront.net/102/6682/61160/61160_poster_pv.jpg)
First Author: J. Maurel
Poster
2011 ASCO Annual Meeting
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
First Author: K. Oliner
Poster
2022 ASCO Annual Meeting
Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).
First Author: Andreas Jay Kind